"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply. Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property. Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation. Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations. Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals). Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals. Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions. Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies. Health Canada regarding regulation about Requirement for reporting of drug shortages. Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world. As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector. As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.